Your mission We are seeking an accomplished Senior scientist of macrophage biology to provide scientific leadership in macrophage biology and immune-stromal interactions, driving target identification, validation and tra…
Your mission Engitix Therapeutics is a pioneering biotechnology company unlocking extracellular matrix (ECM) biology to develop transformative therapeutics for fibrosis and oncology. By combining proprietary human ECM-ba…
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Full-time
postgraduate degree
Private Medical Insurance, Pension, Bonus, Employee Perks
Posted 2d ago
~40 hrs/week
Responsibilities
Lead scientific efforts in macrophage biology and immune-stromal interactions to drive target identification and validation for fibrosis and oncology portfolios. Establish functionality assays and lead a team of scientists to build drug target nomination packages.
Requirements
Requires a PhD with 4+ years of experience or an MSc with 8+ years of experience in drug screening, specifically focusing on immuno-oncology or fibrosis. Must have demonstrable expertise in macrophage biology, multi-colour flow cytometry, and people leadership.
Full job description
Your mission
We are seeking an accomplished Senior scientist of macrophage biology to provide scientific leadership in macrophage biology and immune-stromal interactions, driving target identification, validation and translational strategy across our fibrosis and oncology discovery portfolio.
We are looking for an expert in macrophage biology who will use their experience to establish macrophage-based target screening assays combined with our novel extracellular matrix-based cell models, utilising cellular, immunological, biochemical, molecular biology and functional genomic approaches. You will also provide scientific mentorship and technical guidance to scientists across discovery programmes, champion innovative approaches and emerging technologies in macrophage and immune-stromal biology, and represent macrophage biology expertise within cross-functional project teams.
Key Responsibilities
Establish a suite of macrophage functionality assays to target discovery and drug discovery flowcharts, including activation, cytokine secretion, phagocytosis and efferocytosis assays.
Optimise macrophage target screening-based systems utilising annotated lmw libraries and functional genomic approaches such as siRNA and CrispR library-based approaches.
Lead a small team of immunologists/cell biologists involved in execution of projects across both the internal and external biopartnerships.
Lead the build novel macrophage drug target nomination packages and present case to the leadership for portfolio entry.
Analyse, interpret, report and present results.
Your profile
Key Experience
Demonstrable expertise in macrophage biology, in particular phagocytosis pathways.
Demonstrable experience in target nomination and validation in a biotech or pharmaceutical based setting.
Expertise in the use of multi-colour flow cytometry and IF techniques.
Hands-on experience of key immunological and molecular biology techniques including MSD, RNA/DNA. extraction, qRT-PCR, western blotting, siRNA knockdown.
Have team and direct people leadership experience.
Familiarity with molecular pharmacology and oncology drug development would be an advantage.
Prior working experience in the biotech/pharma industry performing laboratory research would be a further plus.
Qualifications and Competencies
PhD in Biomedical sciences, Immunology, Biochemistry, Biotechnology or related discipline plus 4 years’ experience in drug screening setting or MSc plus 8 years practical experience with a focus on immuno-oncology or fibrosis.
Ability to plan, execute and critically assess experiments independently.
Excellent time-management skills and ability to work to set deadlines.
You will be expected to work well within a team, have strong written and verbal communication skills, as well as IT skills.
You will troubleshoot effectively, work methodically, stay well organised, pay close attention to detail, and maintain accurate records.
Why us?
Be part of a pioneering biotech transforming drug discovery through ECM biology
Work in a collaborative, fast-paced environment with opportunities to shape the future of targeted therapeutics
We offer a competitive package including private medical insurance, pension, bonus, employee perks and more!
About us
Engitix is a growing biotech company based in White City Place, West London. We are dedicated to developing better therapies for advanced fibrosis and solid tumours by leveraging our pioneering extracellular matrix (ECM) platform. Our platform allows the synthesis of realistic in vitro 3D models that serve as tools to transform our ability to identify new targets and biomarkers, determine mechanisms of action and more accurately predict the efficacy of therapeutic candidates.
Join us today in our mission to create a healthier future for patients with life-threatening diseases such as fibrosis and cancer.
Decoding the ECM space to unlock unprecedented therapies for chronic diseases
Industry
Biotechnology Research
Company size
51-200 employees
Founded
2016
Headquarters
London, England
LinkedIn followers
8,865
Total funding
$85M
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours.
Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates.
We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Offices: 21 Lombard Street, London, England EC3V 9AH, GB · Rowalnd Hill Street, London, London NW32PF, GB · 700 Main street, Cambridge, Massachusetts 02139, US
Decoding the ECM space to unlock unprecedented therapies for chronic diseases
Industry
Biotechnology Research
Company size
51-200 employees
Founded
2016
Headquarters
London, England
LinkedIn followers
8,865
Total funding
$85M
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours.
Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates.
We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Offices: 21 Lombard Street, London, England EC3V 9AH, GB · Rowalnd Hill Street, London, London NW32PF, GB · 700 Main street, Cambridge, Massachusetts 02139, US